- Home
- ATHA vs MTEX Comparison
ATHA vs MTEX Comparison
Compare ATHA & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- MTEX
- Stock Information
- Founded
- ATHA 2011
- MTEX 1993
- Country
- ATHA United States
- MTEX United States
- Employees
- ATHA N/A
- MTEX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- MTEX Medicinal Chemicals and Botanical Products
- Sector
- ATHA Health Care
- MTEX Health Care
- Exchange
- ATHA Nasdaq
- MTEX Nasdaq
- Market Cap
- ATHA 18.2M
- MTEX 18.2M
- IPO Year
- ATHA 2020
- MTEX 1999
- Fundamental
- Price
- ATHA $4.72
- MTEX $9.70
- Analyst Decision
- ATHA
- MTEX
- Analyst Count
- ATHA 0
- MTEX 0
- Target Price
- ATHA N/A
- MTEX N/A
- AVG Volume (30 Days)
- ATHA 25.6K
- MTEX 24.0K
- Earning Date
- ATHA 11-06-2025
- MTEX 11-12-2025
- Dividend Yield
- ATHA N/A
- MTEX N/A
- EPS Growth
- ATHA N/A
- MTEX N/A
- EPS
- ATHA N/A
- MTEX N/A
- Revenue
- ATHA N/A
- MTEX $110,411,000.00
- Revenue This Year
- ATHA N/A
- MTEX N/A
- Revenue Next Year
- ATHA N/A
- MTEX N/A
- P/E Ratio
- ATHA N/A
- MTEX N/A
- Revenue Growth
- ATHA N/A
- MTEX N/A
- 52 Week Low
- ATHA $2.20
- MTEX $7.50
- 52 Week High
- ATHA $6.79
- MTEX $16.49
- Technical
- Relative Strength Index (RSI)
- ATHA 61.31
- MTEX 55.20
- Support Level
- ATHA $4.31
- MTEX $9.34
- Resistance Level
- ATHA $4.95
- MTEX $9.97
- Average True Range (ATR)
- ATHA 0.37
- MTEX 0.36
- MACD
- ATHA -0.04
- MTEX 0.01
- Stochastic Oscillator
- ATHA 73.60
- MTEX 72.16
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.